Om

Cellectis S.A. is a clinical-stage biotechnology company focused on gene editing and cell therapy. The company develops allogeneic CAR T-cell product candidates designed for immuno-oncology, along with gene-edited therapies for other serious diseases. Its platform centers on proprietary genome-editing technologies, including TALEN, which are used to engineer off-the-shelf therapeutic candidates intended for broad clinical use. Cellectis also works on hematopoietic stem and progenitor cell applications and other advanced therapeutic programs, positioning the company at the intersection of genetic engineering, immunotherapy, and precision medicine. Headquartered in Paris, France, Cellectis plays a specialized role in the biopharmaceutical market by advancing next-generation therapies built around engineered cells and targeted genetic modification.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I CELLECTIS MED ENDAVU: Køb Cellectis ($ALCLS) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Cellectis, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.